المؤلفون: Han L; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China., Wu L; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China., Yin Q; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China., Li L; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China., Zheng X; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China., Du S; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China., Huang X; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China., Bai L; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address: blci@163.com., Wang Y; Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Center of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu 610072, China. Electronic address: w_yi2022@163.com., Bian Y; Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China; Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address: bianyuan567@126.com.

المصدر: Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2024 Jun; Vol. 128, pp. 155505. Date of Electronic Publication: 2024 Mar 06.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Urban & Fischer Verlag Country of Publication: Germany NLM ID: 9438794 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-095X (Electronic) Linking ISSN: 09447113 NLM ISO Abbreviation: Phytomedicine Subsets: MEDLINE

مواضيع طبية MeSH: Non-alcoholic Fatty Liver Disease*/drug therapy , PCSK9 Inhibitors*/therapeutic use, Animals ; Humans ; Fatty Liver/drug therapy ; Fatty Liver, Alcoholic/drug therapy ; Lipid Metabolism/drug effects ; Liver/drug effects ; Proprotein Convertase 9/metabolism

المؤلفون: Hosseini K; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, 1419733141, Iran., Soleimani H; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran. hamid.r.soleimani90@gmail.com.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, 1419733141, Iran. hamid.r.soleimani90@gmail.com.; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, 1411713139, Iran. hamid.r.soleimani90@gmail.com., Maleki S; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.; School of Medicine, Guilan University of Medical Sciences (GUMS), Rasht, Guilan Province, Iran., Nasrollahizadeh A; Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, 1419733141, Iran., Tayebi S; Centre for Clinical Research Sormland, Uppsala University, Uppsala, SE, Sweden., Nelson J; California Cardiovascular Institute, Fresno, CA, USA., Heffron SP; Center for the Prevention of Cardiovascular Disease, Leon H. Charney Division of Cardiology, NYU Langone Health, New York University Grossman School of Medicine, New York, NY, USA.

المصدر: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2024 Jul 30; Vol. 24 (1), pp. 395. Date of Electronic Publication: 2024 Jul 30.

نوع المنشور: Systematic Review; Meta-Analysis; Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968539 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2261 (Electronic) Linking ISSN: 14712261 NLM ISO Abbreviation: BMC Cardiovasc Disord Subsets: MEDLINE

مواضيع طبية MeSH: Acute Coronary Syndrome*/drug therapy , Acute Coronary Syndrome*/mortality , Acute Coronary Syndrome*/blood , Acute Coronary Syndrome*/diagnosis , Biomarkers*/blood , PCSK9 Inhibitors*, Humans ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/administration & dosage ; Anticholesteremic Agents/therapeutic use ; Cholesterol, LDL/blood ; Drug Administration Schedule ; Dyslipidemias/drug therapy ; Dyslipidemias/blood ; Dyslipidemias/diagnosis ; Dyslipidemias/mortality ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Myocardial Infarction/mortality ; Myocardial Infarction/drug therapy ; Myocardial Infarction/diagnosis ; Myocardial Revascularization ; Observational Studies as Topic ; Randomized Controlled Trials as Topic ; Risk Factors ; Serine Proteinase Inhibitors/adverse effects ; Serine Proteinase Inhibitors/therapeutic use ; Serine Proteinase Inhibitors/administration & dosage ; Time Factors ; Treatment Outcome

المؤلفون: Chen DQ; Department of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China.; The School of Clinical Medicine, Fujian Medical University, Fuzhou, China., Xu WB; Department of Orthopedics, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China., Xiao KY; Department of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China.; The School of Clinical Medicine, Fujian Medical University, Fuzhou, China., Que ZQ; Department of Orthopedics, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China., Feng JY; Department of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China.; The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.; Department of Orthopedics, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China., Sun NK; Department of Orthopedics, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China., Cai DX; Department of Orthopedics, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China., Rui G; Department of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China. reigang@163.com.; The School of Clinical Medicine, Fujian Medical University, Fuzhou, China. reigang@163.com.; Department of Orthopedics, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China. reigang@163.com.

المصدر: BMC musculoskeletal disorders [BMC Musculoskelet Disord] 2024 Jul 16; Vol. 25 (1), pp. 548. Date of Electronic Publication: 2024 Jul 16.

نوع المنشور: Journal Article; Meta-Analysis

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968565 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2474 (Electronic) Linking ISSN: 14712474 NLM ISO Abbreviation: BMC Musculoskelet Disord Subsets: MEDLINE

مواضيع طبية MeSH: Mendelian Randomization Analysis* , Osteoporosis*/genetics , Osteoporosis*/chemically induced , Osteoporosis*/epidemiology , Polymorphism, Single Nucleotide* , Genome-Wide Association Study* , PCSK9 Inhibitors*, Humans ; Proprotein Convertase 9/genetics ; Proprotein Convertase 9/metabolism ; Hydroxymethylglutaryl CoA Reductases/genetics

المؤلفون: Goodman SG; Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Steg PG; Université Paris-Cité, Institut Universitaire de France, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and INSERM U1148, F-75018 Paris, France., Szarek M; CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, 80045 CO, USA.; State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA., Bhatt DL; Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Bittner VA; Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35233, USA., Diaz R; Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, S2000 Rosario, Argentina., Harrington RA; Cornell University, New York, NY 10065, USA., Jukema JW; Department of Cardiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; Netherlands Heart Institute, 3511 EP Utrecht, The Netherlands., White HD; Green Lane Cardiovascular Research Unit, Te Whatu Ora-Health New Zealand, Te Toka Tumai, and University of Auckland, Auckland 1030, New Zealand., Zeiher AM; Department of Medicine III, Goethe University, 60596 Frankfurt am Main, Germany., Manvelian G; Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA., Pordy R; Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA., Poulouin Y; IT&M Stats, Neuilly-sur-Seine 92200, France., Stipek W; Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA., Garon G; Sanofi, Toronto, ON M2R 3T4, Canada., Schwartz GG; University of Colorado School of Medicine, Aurora 80045, CO, USA.

مؤلفون مشاركون: ODYSSEY OUTCOMES Investigators

المصدر: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Jul 16; Vol. 10 (4), pp. 342-352.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium: Internet ISSN: 2055-6845 (Electronic) NLM ISO Abbreviation: Eur Heart J Cardiovasc Pharmacother Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Cholesterol, LDL*/blood , PCSK9 Inhibitors*, Humans ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/therapeutic use ; Biomarkers/blood ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/mortality ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/blood ; Dyslipidemias/drug therapy ; Dyslipidemias/blood ; Dyslipidemias/diagnosis ; Proprotein Convertase 9/metabolism ; Proprotein Convertase 9/immunology ; Randomized Controlled Trials as Topic ; Serine Proteinase Inhibitors/adverse effects ; Serine Proteinase Inhibitors/therapeutic use ; Time Factors ; Treatment Outcome

المؤلفون: Rivera FB; Department of Medicine, Lincoln Medical Center, New York, NY, USA., Cha SW; Cebu Institute of Medicine, Cebu City, Philippines., Magalong JV; College of Medicine, San Beda University, Manila, Philippines., Bantayan NRB; University of the Philippines College of Medicine, Manila, Philippines., Cruz LLA; University of the Philippines College of Medicine, Manila, Philippines., Arias-Aguirre E; Cebu Institute of Medicine, Cebu City, Philippines., Aguirre Z; Cebu Institute of Medicine, Cebu City, Philippines., Varona MC; Cebu Institute of Medicine, Cebu City, Philippines., Co EMF; Cebu Institute of Medicine, Cebu City, Philippines., Lumbang GNO; Cebu Institute of Medicine, Cebu City, Philippines., Enkhmaa B; Division of Endocrinology, Diabetes & Metabolism, UC Davis Health, Davis, CA, USA.

المصدر: Current medical research and opinion [Curr Med Res Opin] 2024 Jul; Vol. 40 (7), pp. 1103-1121. Date of Electronic Publication: 2024 Jun 11.

نوع المنشور: Journal Article; Meta-Analysis

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , PCSK9 Inhibitors* , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use, Humans ; Female ; Proprotein Convertase 9/metabolism ; Male ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/therapeutic use ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/epidemiology

المؤلفون: Zhang N; Department of Laboratory Medicine, Peoples Hospital of Deyang City, No 173, the First Section of North Taishan Road, Deyang, 618000, China. znd1984@126.com., Ji C; Department of Laboratory Medicine, Peoples Hospital of Deyang City, No 173, the First Section of North Taishan Road, Deyang, 618000, China., Liu L; Department of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China., Ye E; Department of Laboratory Medicine, Peoples Hospital of Deyang City, No 173, the First Section of North Taishan Road, Deyang, 618000, China., Yuan C; Department of Laboratory Medicine, Peoples Hospital of Deyang City, No 173, the First Section of North Taishan Road, Deyang, 618000, China.

المصدر: Calcified tissue international [Calcif Tissue Int] 2024 Jul; Vol. 115 (1), pp. 53-62. Date of Electronic Publication: 2024 May 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: United States NLM ID: 7905481 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0827 (Electronic) Linking ISSN: 0171967X NLM ISO Abbreviation: Calcif Tissue Int Subsets: MEDLINE

مواضيع طبية MeSH: Osteoporosis*/epidemiology , Mendelian Randomization Analysis* , PCSK9 Inhibitors* , Bone Density*/drug effects, Humans ; Middle Aged ; Female ; Male ; Adult ; Mediation Analysis ; Cholesterol, LDL/blood ; Proprotein Convertase 9

المؤلفون: Wagner J; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States., Park LM; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States., Mukhopadhyay P; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, United States., Matyas C; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, United States., Trojnar E; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, United States., Damadzic R; Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States., Jung J; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States., Bell AS; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States., Mavromatis LA; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States; Department of Medicine, NYU Grossman School of Medicine, New York, New York, United States., Hamandi AM; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States., Rosoff DB; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States; NIH-Oxford-Cambridge Scholars Program, Radcliffe Department of Medicine, University of Oxford, UK., Vendruscolo LF; Stress and Addiction Neuroscience Unit, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, MD, United States., Koob GF; Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, United States., Pacher P; Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, United States., Lohoff FW; Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, United States. Electronic address: falk.lohoff@nih.gov.

المصدر: Brain, behavior, and immunity [Brain Behav Immun] 2024 Jul; Vol. 119, pp. 494-506. Date of Electronic Publication: 2024 Apr 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8800478 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2139 (Electronic) Linking ISSN: 08891591 NLM ISO Abbreviation: Brain Behav Immun Subsets: MEDLINE

مواضيع طبية MeSH: Oxidative Stress*/drug effects , Ethanol* , Neurons*/metabolism , Neurons*/drug effects , PCSK9 Inhibitors*/pharmacology , Proprotein Convertase 9*/metabolism , Brain*/metabolism , Brain*/drug effects , Antibodies, Monoclonal, Humanized*/pharmacology, Animals ; Male ; Rats ; Alcoholism/metabolism ; Alcoholism/drug therapy ; Microglia/metabolism ; Microglia/drug effects ; Receptors, LDL/metabolism ; Rats, Sprague-Dawley ; Disease Models, Animal

المؤلفون: Kehinde IO; Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa.; Department of Pharmaceutical and Medicinal Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria., Akawa O; Department of Pharmaceutical and Medicinal Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria., Adewumi AT; Department of Life and Consumer Sciences, University of South Africa, Florida Campus, Johannesburg, South Africa., Rabbad AH; Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa., Soliman MES; Molecular Bio-computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, South Africa.

المصدر: Journal of cellular biochemistry [J Cell Biochem] 2024 Jul; Vol. 125 (7), pp. e30581. Date of Electronic Publication: 2024 May 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8205768 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4644 (Electronic) Linking ISSN: 07302312 NLM ISO Abbreviation: J Cell Biochem Subsets: MEDLINE

مواضيع طبية MeSH: PCSK9 Inhibitors* , Molecular Dynamics Simulation* , Proprotein Convertase 9*/metabolism , Proprotein Convertase 9*/chemistry , Atherosclerosis*/drug therapy , Atherosclerosis*/metabolism, Humans ; Drug Design ; Cardiovascular Diseases/drug therapy ; Pharmacophore

المؤلفون: Kraaijenhof JM; Department of Vascular Medicine Amsterdam University Medical Centers, University of Amsterdam Amsterdam The Netherlands., Cronjé HT; Department of Public Health, Section of Epidemiology University of Copenhagen Copenhagen Denmark., Hovingh GK; Department of Vascular Medicine Amsterdam University Medical Centers, University of Amsterdam Amsterdam The Netherlands., Nurmohamed NS; Department of Vascular Medicine Amsterdam University Medical Centers, University of Amsterdam Amsterdam The Netherlands.; Department of Cardiology Amsterdam University Medical Centers, Vrije Universiteit Amsterdam Amsterdam The Netherlands., Gill D; Department of Epidemiology and Biostatistics, School of Public Health Imperial College London London United Kingdom., Zagkos L; Department of Epidemiology and Biostatistics, School of Public Health Imperial College London London United Kingdom.

المصدر: Journal of the American Heart Association [J Am Heart Assoc] 2024 Jun 18; Vol. 13 (12), pp. e033190. Date of Electronic Publication: 2024 Jun 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE

مواضيع طبية MeSH: PCSK9 Inhibitors* , Proteomics*/methods , Proprotein Convertase 9*/genetics , Proprotein Convertase 9*/metabolism, Humans ; Anticholesteremic Agents/therapeutic use

المؤلفون: Zhang L; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China., Wang X; School of Health Policy and Management, Nanjing Medical University, Nanjing, China., Yao H; School of Pharmacy, Nanjing Medical University, Nanjing, China., Ding B; School of Pharmacy, Nanjing Medical University, Nanjing, China., Gao X; School of Health Policy and Management, Nanjing Medical University, Nanjing, China.; Simcere Zaiming Pharmaceutical Co., Ltd., Nanjing, China., Li X; School of Health Policy and Management, Nanjing Medical University, Nanjing, China. xinli@njmu.edu.cn.; School of Pharmacy, Nanjing Medical University, Nanjing, China. xinli@njmu.edu.cn.; Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China. xinli@njmu.edu.cn.

المصدر: International journal for equity in health [Int J Equity Health] 2024 Jun 05; Vol. 23 (1), pp. 116. Date of Electronic Publication: 2024 Jun 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147692 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-9276 (Electronic) Linking ISSN: 14759276 NLM ISO Abbreviation: Int J Equity Health Subsets: MEDLINE

مواضيع طبية MeSH: Interrupted Time Series Analysis* , PCSK9 Inhibitors* , Drug Costs* , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/economics, Humans ; China ; Health Services Accessibility/statistics & numerical data ; Anticholesteremic Agents/therapeutic use ; Anticholesteremic Agents/economics ; Health Policy